Genprex, Inc. (GNPX) - 10-Q Summary for Period Ended September 30, 2025
Business Context and Reporting Period
Genprex, Inc. is a clinical-stage gene therapy company focused on oncology (REQORSA) and diabetes (GPX-002) programs. This report covers the quarterly period ended September 30, 2025. The company is currently listed on The Nasdaq Capital Market but faces delisting risks due to non-compliance with minimum bid price and stockholders' equity requirements. To address this, the company completed a 1-for-50 reverse stock split on October 21, 2025. The company operates as a single segment and has sustained substantial losses since inception with no product revenue.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(3,799,240) | $(4,315,987) | $(12,438,742) | $(16,780,702) |
| Net Loss Per Share (Basic/Diluted) | $(5.00) | $(61.65) | $(23.00) | $(344.92) |
| Operating Expenses | $3,345,913 | $4,323,438 | $11,996,987 | $16,838,438 |
| Cash and Cash Equivalents (End of Period) | $1,103,315 | $1,488,281 | $1,103,315 | $1,488,281 |
| Net Cash Used in Operating Activities (YTD) | $(11,212,938) | $(14,053,136) | $(11,212,938) | $(14,053,136) |
| Net Cash Provided by Financing Activities (YTD) | $10,714,593 | $8,029,143 | $10,714,593 | $8,029,143 |
| Total Stockholders' Equity | $767,807 | $1,664,971 | $767,807 | $1,664,971 |
Note: Per share data has been retroactively adjusted for the 1-for-50 reverse stock split completed in October 2025.
Material Changes vs. Prior Period
- Expense Reduction: Net loss decreased by 12% in Q3 and 26% YTD compared to the prior year periods. This improvement is primarily attributed to the closure of the Acclaim-2 clinical trial and significant expense reduction strategies, including reduced headcount (from 19 to 13 employees) and lower professional service fees.
- Financing Activity: The company raised approximately $10.7 million in net proceeds from financing activities YTD 2025, primarily through an At-The-Market (ATM) facility and a new Equity Line of Credit (ELOC) with Lincoln Park Capital Fund, LLC.
- Derivative Liability: A derivative liability of $243,000 was recorded as of September 30, 2025, related to the ELOC agreement, which did not exist in the prior period.
- Stock Structure: The company executed a 1-for-50 reverse stock split in October 2025 to regain compliance with Nasdaq listing requirements.
Guidance, Outlook, and Risks
- Liquidity and Going Concern: Management estimates current cash resources will fund operations into March 2026. However, the filing explicitly states there is "substantial doubt" about the company's ability to continue as a going concern due to recurring losses and the need for additional financing.
- Clinical Pipeline:
- Acclaim-1 (NSCLC): Enrolling in Phase 2a expansion; interim analysis expected in H2 2026.
- Acclaim-3 (SCLC): Enrolling in Phase 2 expansion; interim analysis expected in H2 2026.
- Acclaim-2: Enrollment ceased in August 2024 due to resource prioritization.
- Diabetes (GPX-002): Preclinical studies ongoing; plans to submit an IND request by the end of 2025.
- Nasdaq Compliance: The company received notices of non-compliance regarding minimum bid price ($1.00) and minimum stockholders' equity ($2.5 million). A hearing was requested, and an extension was granted until October 31, 2025, to demonstrate compliance. The reverse stock split is a key remediation step.
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting, specifically regarding segregation of duties and lack of accounting depth. Remediation plans are underway.
- Subsequent Financing: Following the quarter end, the company completed two registered direct offerings in October 2025, raising approximately $5.6 million in net proceeds, and continued sales under the ATM and ELOC facilities.
Investor Verification Checklist
- Cash Runway: Verify if the $1.1 million cash balance and subsequent October financing are sufficient to reach the March 2026 target given the high burn rate.
- Nasdaq Status: Confirm if the 1-for-50 reverse stock split successfully restored compliance with the $1.00 minimum bid price and $2.5 million equity requirements.
- Dilution Impact: Assess the dilution effect from the recent October 2025 registered direct offerings and the ongoing ELOC facility.
- Internal Controls: Monitor progress on remediation of material weaknesses in financial reporting to ensure future financial statement reliability.
- Clinical Milestones: Track enrollment progress for Acclaim-1 and Acclaim-3 trials, as delays could accelerate cash consumption.